Context Management of locally recurrent prostate cancer after definitive radiotherapy
remains controversial due to the perceived high rates of severe genitourinary (GU) and …

Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for
oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to …

Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …

Importance Despite evidence demonstrating an overall survival benefit with up-front
hormone therapy in addition to established synergy between hormone therapy and …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …